Kwality Pharmaceuticals Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Kwality Pharmaceuticals reported oncology revenue of INR30-35 crores for the quarter and reiterated a full-year FY27 revenue target of over INR700 crores with EBITDA margins between 26% to 27%. Management discussed registration progress across the general facility, oncology, biological and hormone units, and addressed debtor days, capex plans, and a proposed change of statutory auditor to KPMG. The company also detailed longer-term revenue expectations from its hormone, biosimilar and Erythropoietin programs extending to FY29 and FY30.
Kwality Pharmaceuticals reported Q4 FY26 revenue of Rs157.1 crore, up 35.8% year-on-year, and full-year FY26 revenue of Rs503 crore, up nearly 36% from Rs370 crore in FY25. EBITDA margins expanded from 22% to 24% and profit after tax grew 69% to Rs67 crore, with management citing improved cash conversion cycle and recovery of delayed Middle East receivables. Management reiterated FY27 targets of Rs650-700 crore revenue and Rs100 crore PAT, alongside a longer-term aspiration of Rs1,000 crore revenue by FY29.